日本語 >>
TOP page
Journal
Presentation
（Last updated : 2024-01-10 19:13:38）
Seiko Sugiyama
Department
Kawasaki Medical School Kawasaki Medical School, Department of Dermatology,
Position
Assistant Professor
■
Journal
1.
2023/09/11
Biomarkers for predicting immune reconstitution inflammatory syndrome in dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective observational study with a case series
2.
2023/05/14
Positron emission tomography and computed tomography imaging in primary cutaneous nocardiosis with osteomyelitis clinically mimicking soft tissue sarcoma
3.
2023/04/17
Dramatic deterioration or new-onset dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid after COVID-19 vaccination: A possible manifestation of immune reconstitution inflammatory syndrome
4.
2022/07
Clinical features of dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid in Japan: A nationwide retrospective observational study.
5.
2022/06
Anti-Cytomegalovirus Therapy: Whether and When to Initiate, Those Are the Questions
6.
2022/06
Neutrophil to lymphocyte ratio is predictive of severe complications and mortality in patients with dipeptidyl peptidase-4 inhibitor-associated bullous pemphigoid: A retrospective longitudinal observational study
7.
2022/03/03
Case Report: Appearance of Various Disease-Specific Antibodies After the Onset of Dipeptidyl Peptidase-4 Inhibitor-Associated Bullous Pemphigoid.
8.
2022/02/27
Drug allergy and non-HIV immune reconstitution inflammatory syndrome
9.
2021/01/13
Risk factors for cytomegalovirus reactivation in autoimmune bullous disease patients on immunosuppressive therapy
10.
2020/08/13
Systemic capillary leak syndrome triggered by anti-programmed death 1 checkpoint inhibitor in psoriasis.
11.
2020/06/11
Acquired Haemophilia A in DPP4 Inhibitor-induced Bullous Pemphigoid as Immune Reconstitution Syndrome.
12.
2019/09
Prurigo nodularis as a sweat gland/duct-related disorder: resolution associated with restoration of sweating disturbance.
13.
2019/04
Postherpetic hypohidrosis-related isotopic response associated with lichen planus and lichen amyloidosis.
14.
2019/02
A Case of interstitial pneumonia during ustekinumab treatment in a patient with psoriatic arthritis
15.
2013/04
YKL-40 is a serum biomarker reflecting the severity of cutaneous lesions in psoriatic arthritis.
16.
2012/11
Eccrine poromatosis associated with polychemotherapy.
17.
2011/12
Granulysin-producing cytotoxic T cells in the mucocutaneous lesions of Behcet disease: a distinct inflammatory response from erythema nodosum.
18.
2011/10
YKL-40 (chitinase 3-like-1) as a biomarker for psoriasis vulgaris and pustular psoriasis.
19.
2011/05
Markedly elevated serum levels of calcium-binding S100A8/A9 proteins in psoriatic arthritis are due to activated monocytes/macrophages.
20.
2007/12
A novel homozygous mutation of the
EVER1/TMC6 gene
in a Japanese patient with epidermodysplasia verruciformis.
Display 5 items
Display all(20)
■
Presentation
1.
2023/05/11
The predictive and diagnostic biomarkers of immune-related adverse events vary by the affected organ （Poster notice，General）
2.
2022/12/02
Cytokine profiles for predicting the development of COVID-19 vaccine-associated bullous pemphigoid （Speech，General）
3.
2021/12/03
Occurrence of immune reconstitution inflammatory syndrome can be predicted by cytokine profiles in dipeptidyl peptidase-4 inhibitors-associated bullous pemphigoid （Speech，General）
4.
2020/12/11
Neutrophil-to-lymphocyte ratio as a useful biomarker can predict outcomes in dipeptidyl peptidase-4 inhibitor associated bullous pemphigoid （Poster notice，General）
